Objective: To study the pharmacodynamic and pharmacokinetic properties of oral and intravenous methylergometrine upon uterine motility during menstruation. Study-design: Intra-uterine pressure was measured in six volunteers with a fluid-filled spongetipped catheter during menstruation. Methylergometrine was given orally (0.5 mg) or intravenously (0.2 mg) in a cross-over design. Results: After intravenous administration, a fast increase of the frequency of uterine contractions and basal tone occurred with a decrease of amplitude, lasting at least 30 min. Oral administration had a late and less marked effect on uterine motility. An intra venous dose administered 24 h after an oral dose had no effect on uterine motility. Pharmacokinetic data, such as the maximum plasma concentration (Cmax), the time at which Cmax is reached (tmax) and the half-life of absorption a^so demonstrated large individual variations after oral administration. Conclusion: Oral administration of methylergometrine had an unpredictable and late effect on uterine motility on the menstruating uterus, probably due to an unpredictable bioavailability, in contrast with the fast and predictable effect after intravenous administration.
Introduction
Uterine activity can be stimulated during menor rhagia or the postpartum period. Secale alkaloids were one of the earliest stimulants in obstetrics, applied as treatment or prevention of postpartum haemorrhage first noticed by Caspar Schwenkfeldt in 1600 [1] . In con trast to oxytocin and prostaglandins, secale alkaloids can be given orally, which has the advantage of easy drug administration. Pharmacokinetic and phar macodynamic data on oral secale alkaloids are, how ever, sparse.
Postpartum haemorrhage is responsible for 150 000 deaths worldwide a year [2] , -98% of which occur in developing countries [3] . In these countries, active man agement of the third stage of labour with oxytocics is particularly advocated [4] . Intramuscular oxytocin, the standard care in the third stage, is not available to all women. Oral use of methylergometrine, although not recommended by the manufacturer, may be considered as an easy alternative. Before starting worldwide distri bution o f these tablets, extensive studies on the stability, pharmacokinetic and pharmacodynamic parameters and clinical effects had to be performed.
This study simultaneously assessed pharmaco dynamic and pharmacokinetic parameters of oral and intravenous methylergometrine on uterine muscle in six non-pregnant women at the second day of the menstrual cycle (CD 2), because at CD 2 the menstruating uterus resembles the uterus in the postpartum period [5] .
Materials and methods

Subjects
Six non-pregnant women with regular menstrual cycles volunteered for the pharmacokinetic and phar (1995) [101] [102] [103] [104] [105] [106] [107] macodynamic studies with methylergometrine. They were screened for possible contra-indications such as cardio-vascuar disease, chronic obstructive lung disease, fibroids or uterine surgery, and should have had a tubal ligation to prevent any negative interaction with fertili ty. This study was approved by the Committee for Experimental Research Involving Human Subjects (CEOM) of the University Hospital Nijmegen Sint Radboud, Nijmegen, the Netherlands.
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Intra-uterine pressure (IUP) recordings
Intra-uterine pressure was recorded using a fluidfilled sponge-tipped catheter [5, 6] , The portio vaginalis was cleansed and disinfected with iodine. The open-tip sponged catheter was inserted over a guiding tube. The uterus was manipulated as less as possible in order not to cause any interference with the uterine contractility pattern. A gauze was left in the vagina while the catheter was fixed on the upper leg to prevent expulsion. The catheter was connected to a pressure transducer, which was connected to a computer. The woman was in the supine position during the registration. The pressure transducer was fixed on the mattress, being the level of the surface supporting the supine volunteer. Zero pres sure was set at atmospheric pressure at this "mattress5 level [7] . The location of the catheter was controlled by asking the volunteer to cough. Proper intra-uterine posi tion then showed a pressure elevation (about 10 mmHg).
Because the presence of any foreign body in utero causes an increase of basal pressure level for at least 20 min [8] , we waited 30 min to allow the 'cyclic-specific* pattern to develop and then started the study. After re cording uterine activity at least 60 min after the insertion of the sponge-tipped catheter, methylergometrine was administered either intravenously or orally. The registration ended when the catheter was expelled. If the catheter remained in its position, it was removed after 5 h. A trans-urethral catheter was inserted to provide con tinuous bladder drainage because filling of the bladder was reported to effect IUP [8] .
Digitalization o f the signal (IUP)
The intra-uterine pressure signal was filtered by a 0.65 Hz filter. Total noise with shortened impulse was measured over 15 min (mean ± S.D. = 0.442 ± 0.084), which did not disturb the general activity pattern.
To obtain an accurate signal, the range of the mercury scale had been set to 0-150 mmHg. Measurements were made using the DTX/plus pressure transducer (Viggospectramed, Oxnard, California, USA) and a specially developed amplifier before the signal was fed to a per sonal computer (DASH-8, Metrabyte). Special care had been taken for patient safety using a safety chart. The software had been developed with Borland C++ (Scotts Valley, California, USA). Events were marked by spe cial keys. Recordings were stored in files which were Microsoft Excel compatible. The resolution of the whole system was about 0.5 mmHg. The system was calibrated electronically and mechanically (mmHg).
Pharmacodynamics
Mechanical uterine activity was measured by IUP recordings. Contractions were expressed in IUP cycles. An IUP cycle was defined as a transitory rise above the basal tone. To describe uterine activity, IUP cyclespecific parameters were distinguished: frequency (F), basal tone (BT), intensity (I) and amplitude (A = I -BT). The number of IU P cycles in a 5 min period were recorded and the mean value of F, BT and A of the IUP cycles in each 5 min period were calculated,
The mean values o f these parameters (F, BT and A) during the 30 min registration of the 'cyclic-specific5 pat tern were regarded as baseline values and set at 100%. For each parameter the relative increase in a 5 min period was expressed as a percentage of baseline value and plotted against time. For each IUP recording, the area under the curve (/i UQ was calculated in time inter vals of 30 min from the time of drug administration until 90 min after administration.
IUP recordings
Registration took place at the 2nd day of the cycle (CD 2) of two subsequent menstrual cycles to rule out a possible refractory period, i.e. uterine insensitivity to methylergometrine. In addition four women were also examined when 0.2 mg methylergometrine was injected on the third day of menstruation of the second cycle (CD 3), i.e. 24 h after the oral test.
Drugs
Pure methylergometrine (reference substance 108) was obtained from Sandoz Pharma AG (Basel, Switzerland). Methylergometrine maleate (0.125 mg tab let Methergin®; equivalent to 0.095 mg free base) was obtained from Sandoz Germany, Nürnberg; batch num ber 3001. Methylergometrine maleate (0.20 mg/ml injec table solution; equivalent to 0.152 mg free base) was obtained from Sandoz, Uden, The Netherlands; batch number 475 M FD 920812. These methylergometrine batches fulfilled the requirements of standard quality control criteria.
Dosage
Dosage A . For the assessment of the bioavailability of methylergometrine, a cross-over design was used for the intravenous and oral administrations. The interval be tween both administrations was one menstrual cycle. An intravenous dose o f 0.2 mg methylergometrine maleate was injected at CD 2 after a standard breakfast contain ing two sandwiches, no cheese and unrestricted amounts of coffee or tea by all subjects. The drug was ad ministered at least 1 h after insertion o f the IUP catheter. Care was taken that all of the intravenous dose was administered by cleaning the intravenous dosage line with 2 ml 0.9% saline. An oral dose of 0.5 mg methylergometrine maleate was given after a standard breakfast on the second day of the next menstrual cycle.
Dosage B. An additional intravenous administration was administered in four women on CD 3, 24 h after oral administration at CD 2.
Sampling
Oral administration. Blood samples o f 5 ml were col lected through an intravenous (IV) internal catheter (Venflon® 1.0 mm OD) in tubes containing 0.5 mg Li heparin at 0, 10, 20, 30, 60, 90, 180 and 240 min.
Intravenous administration. Intravenous administra tion of methylergometrine took place for 1 min in the opposite arm to where the Venflon was located. In addi tion to the sampling times as described under oral ad ministration, two extra samples were taken at 3 and 5 min after the start of the injection. After centrifugation of the blood samples at 11 000 g for 5 min, plasma sam ples from both the oral and intravenous groups were stored at -20°C pending analysis.
Drug analysis
Drug analysis was performed by High Pressure Liq uid Chromatography (HPLC) according to de Groot et aL [9] .
Pharmacokinetic analysis
The pharmacokinetic parameters were calculated from a two-compartment model after intravenous ad ministration, and from a one-compartment model with lag-time fitted to oral data (MW/Pharm computer pro gram, Mediware®, Groningen, the Netherlands) [10] . Cmax is the maximum plasma concentration read from the fitted plasma concentration-time curve (r2 > 0.98), and tmax the time at which Cmax occurs. The ¿^-v alu es were calculated from ln(2)//3, where /3 is calculated by log-linear regression analysis of the terminal log-linear phase. The tJ/2absorption and tJ/2oi were obtained by line feathering and linear regression analysis.
Mean absorption time (MAT) was used as a measure o f the rate of absorption and calculated as the difference between (M RTpo -tlag) and M RTiv.
AUC0^« is the area under the plasma concentration time curve and was calculated using the linear trapezodial rule with extrapolation of / = oo, using C,//3 with Ct being the last measured concentration. 
Results
3.1, Subjects
Six women entered the study. Their mean age was 38 =fc 5 years, mean weight 59 ± 5 kg and mean length 167 db 6 cm (mean ± S.D.). The blood pressure ranged between normal values; mean systolic pressure 113 =fc 11 mmHg, mean diastolic pressure 73 ± 8 mmHg. They all had a uterus in an anteversionanteflexion position. Table 1 A, intravenous methylergometrine (ME) (0,2 mg) without preceding oral ME; B, intravenous ME (0.2 mg) with preceding oral ME (0.5 mg).
Pharmacokinetic results
Abbreviations: see Table 1 .
and the steady state volume of distributipn ( Vss) was 50.5 ± 5.8 1/h. After oral administration of methyl ergometrine, the lag time was 0.30 ± 0.08 h, the absorp tion half-life (tj/2abs) was 0-14 ± 0.12 h, the' mean absorption time {MAT) was 0.40 ± 0.35 h and the elimination half-life (tj/2p) was 1.59 =t 0.32 h. Total body clearance was 30.0 ± 8.8 1/h and the volume of distribution was 68.6 ± 24 1. The biovailablity (F) was subject dependent and ranged between 47.7% and 94.6%, with the assumption that the total body clearance is similar after intravenous and oral adminis tration. Large inter-individual differences in Cmax (53% C.V.), tmax (56% C.V.) and tm abs (85% C.V.) after oral administration were recorded. Two volunteers showed prolonged absorption and were left out in the calcula tion of the means. Table 2 summarizes the pharmacokinetic parameters after additional intravenous administration of 0.2 mg methylergometrine in four women when it was injected on CD 3 of the second cycle, i.e. 24 h after the oral ad ministration. There is no difference in pharmacokinetic parameters after the intravenous dosage at CD 2 of the first menstrual cylce and at CD 3 of the second cycle (P > 0.05).
3.3,
Pharmacodynamic results -effect of methylergometrine on IUP When 0.2 mg methylergometrine was injected in travenously on CD 2 of the first menstrual cycle, the fre quency of uterine contractions and basal tone increased in all six women, while the amplitude of the uterine con tractions decreased. This effect lasted at least 90 min with a maximum at 30 min. Within one woman the effect of 0.5 mg oral methylergometrine on uterine activ ity on CD 2 of the second menstrual cycle was much less marked than after the intravenous administration. basal tone and decrease in amplitude of uterine contrac tions after intravenous administration of 0.2 mg methylergometrine. Within 3 min after the injection, the frequency of contractions increased by 350% to a maxi mum of 650% as a percentage of the baseline frequency value. After 35 min the increase of frequency was reduced to 200% of the baseline value. The basal tone showed a fairly identical pattern with a maximum increase o f 700% within 10 min after drug administra tion. Basal tone remained increased to 550% of its base line value until 70 min after drug administration. The amplitude decreased to 30% of its baseline value within 10 min and remained reduced during further recording. The right panel shows the late and less marked effect after oral administration of 0.5 mg methylergometrine. An increase in frequency of 240% occurred 35 min after drug administration. A maximum increase of 320% of the baseline value was reached after 50 min. An increase in basal tone was seen after 30 min with maximum values of 700% after 50 min. The basal tone remained elevated compared to the baseline values. The amplitude decreased to 17% after 55 min, but returned to its base line value 80 min after drug administration. Fig, 2 illustrates the mean frequency, mean basal tone and mean amplitude in 5 min periods after oral and in travenous administratios (A, left panel) and after intra venous administration at CD 2 and the day after an oral test CD 3 (B, right panel). The values used in the figure are the mean values of the 6 volunteers.
The figure clearly illustrates the different patterns in F, BT and A after intravenous or oral administrations (left panel). It also shows that there is hardly any uterine response to a 0.2 mg intravenous dose if this is preceded by 0.5 mg methylergometrine 24 h before (right panel). Table 3 shows the A UC of the individual IU P record ings, When AUC 30 min before drug administration (AU C^q^o) is compared to AUC 30 min after drug administration (AUC0^30), a marked increase in AUC is seen after intravenous administration and hardly any after oral administration. After oral administration, a (slight) change in A UC is seen in the period between 30 and 60 min after the intake of 0.5 mg methyl ergometrine.
When 0.2 mg methylergometrine was injected 24 h after the oral test, hardly any changes in B T , F and A of intra-uterine pressure were recorded (Fig, 2B) . The A UC was less increased than after the injection of 0.2 mg methylergometrine at CD 2 of the first menstrual cycle and even less than after the oral administration of 0.5 mg methylergometrine (Table 3) .
Side effects
Three women experienced dizziness after intravenous injection, while all experienced abdominal cramps within 5 min after intravenous administration. After an oral dose, three out of six experienced abdominal cramps approximately 1 h after drug administration.
Discussion
This study demonstrates the feasability of assessing the effect o f uterine stimulation during human menstru-ation with pharmacokinetic data. Although uterine stimulation is not frequently used to treat menorrhagia, this model may provide indirect evidence for the more important issue of postpartum haemorrhage. It is likely that the human uterus functions similarly during men struation and labour, i.e. in providing an expelling force. This can be demonstrated by the intra-uterine pressure patterns, which are similar in both situations [5, 11, 12] . The same holds true for coagulating and fibrinolytic properties within the uterine cavity [13, 14] .
It is also our experience that the method used in this study, i.e. the sponge-tipped fluid-filled catheter, is more reliable in the non-pregnant uterus than in the postpar tum uterus because of the increased degree of expulsion in the latter. In the postpartum uterus, only transabdominally placed open-tip catheters are thought to provide the most reliable quantative information on uterine contractility. This procedure, however, en counters medical and ethical contra-indications when used just for research purposes. Micro-transducers at the catheter tip were not used because of possible ar tifacts [15] and the impossibility of calibration during the recording [16] .
The most striking observation was the wide variation of bioavailability of oral methylergometrine, which cor responds with the recently published data found in male volunteers [9] ; former data on methylergometrine [17] described only a fast absorption of methylergometrine tablets.
Uterine motility was reflected in BT, F, A and AUC of the IUP cycle. The values of two AUC_30^0 in the same volunteers in different tests were not similar which makes it irrational to compare AUC0_90 after intra venous and oral administrations within the same volunteer (e.g. volunteer 5). In one volunteer (volunteer 5), F, B T and A showed quantitative variations at CD 2 of two subsequent menstrual cycles before administra tion of methylergometrine. This explains why differ ences in AUC"30^q existed in the subsequent menstrual cycles in one volunteer. Volunteers 3, 5 and 6 (Table 3) had a higher B T before oral administration than before the injection of methylergometrine. This explains why A UCq^m is larger after oral than intravenous adminis tration. The changes in BT, F, A and AUC after oral ad ministration of methylergometrine show a rather late and unpredictable stimulating effect on uterine motility. They reflect the same wide variation as observed in the pharmacokinetic data after oral administration.
The observation of the strongly diminished effect of intravenously-administered methylergometrine 24 h after oral administration suggests a long-lasting receptor blockade. It seemed as if the uterus was insensitive to the methylergometrine dose. The first dose may affect and change the uterine receptors for methylergometrine.
This could explain the insensitivity to the second dose of 0.2 mg methylergometrine in postpartum uteri lasting 3 h, measured by external tocography as reported in 1959 [18] and observed in our experiments even 24 h after oral administration of 0.5 mg methylergometrine, Methylergometrine probably blocks a-receptors in the inner layer, specifically affecting the basal tone of this layer [19] [20] [21] .
S. Conclusion
Oral administration of methylergometrine shows a late and unpredictable effect on the menstruating uterus in contrast to the fast and predictable effect of an intra venous dose. A relation between plasma concentration and pharmacodynamic effect could not be demonstrated after oral administration. Therefore, oral secale alka loids cannot be advocated for either the treatment of menorrhagia or for postpartum haemorrhage.
